Could stem cells step in to replace lost neurons in Parkinson’s disease? In three Phase 1 clinical trials, scientists tested lab-grown dopaminergic cells in small cohorts to assess safety and look for ...

In the Alzheimer’s brain, microglia diversify into several activation states. What controls this specialization? In a preprint posted to bioRxiv on October 13, scientists led by Martin Kampmann at the ...

Retrotransposons are evolutionarily ancient genes that “jump” around the human genome leaving a slew of repeat nucleotide sequences in their wake. These repeats can disturb normal gene function.

With one plasma p-tau217 test being approved just last May by the U.S. Food and Drug Administration and others likely to follow suit this year, this marker is poised to change the way clinicians ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

Today the U.S. Food and Drug Administration’s advisory committee gave the nod to donanemab, clearing the way for its marketing approval. All 11 members voted that the antibody was effective for people ...

Research over the last decade has shown that aggregated Aβ seeds can be transferred between people during rare medical procedures, sparking amyloidosis in the recipient. Could this result in ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...